Conference Coverage

VIDEO: New MS database could change practice


 

AT THE CMSC/ACTRIMS ANNUAL MEETING

DALLAS – The North American Registry for Care and Research in MS, a national database of multiple sclerosis patients, and the first of its kind, is expected to change multiple sclerosis care in the next decade.

The NARCRMS, which acts as both a database and a registry, will collect patient information from MS centers across the United States over time. It is modeled after the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and it’s a collaboration between the industry and MS centers to create an open source database, "available in real time to patients, physicians, and industry," Dr. Kottil W. Rammohan, professor of clinical neurology and director of the MS center of excellence at the University of Miami, said at a meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis.

The NARCRMS, not to be confused with NARCOMS (North American Research Committee on Multiple Sclerosis), hasn’t launched yet – it will be established later this year – but the leaders have great hopes for it, and say that it will help find answers to questions that exist because of a lack of data.

For instance, there are very few head-to-head trials comparing drugs with each other. The database could provide insight and the answer, said Dr. Rammohan.

More information and details will be available once the database is launched, but Dr. Rammohan provided an overview of the NARCRMS, and explained why a database hasn’t been established until now.

Dr. Rammohan said he had no relevant financial disclosures.

nmiller@frontlinemedcom.com

On Twitter @naseemmiller

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Autoimmune disease coalition seeks to increase physician knowledge
MDedge Internal Medicine
AAN calls oral cannabinoids effective for MS pain, spasticity
MDedge Internal Medicine
Natalizumab reduced biomarkers of intrathecal inflammation in progressive MS
MDedge Internal Medicine
Spinal fluid may help flesh out natalizumab-associated PML diagnosis
MDedge Internal Medicine
VIDEO: New meds, remyelination therapies move ahead in multiple sclerosis
MDedge Internal Medicine
Proposed neuromyelitis optica diagnostic criteria reflect new disease understanding
MDedge Internal Medicine
Dalfampridine’s effects on walking ability in MS extend to 24 weeks
MDedge Internal Medicine
Lesion length, number correspond to neuromyelitis optica Dx
MDedge Internal Medicine
Alemtuzumab found to reduce brain lesions, volume loss
MDedge Internal Medicine
iPad app could change how MS is measured, treated
MDedge Internal Medicine